Table 4 Summary of previously published series
Article | Histological subtype | No of samples | Smoking status | Concordance PT/M | Analysis within PT | Concordance within PT | Method | Mutation type | Metastatic sites |
|---|---|---|---|---|---|---|---|---|---|
Yatabe et al. 2011[17] | ADC (77) | 77 | 100 | qPCR | L858R | Lymph nodes | |||
Fragment analysis | DEL19 | ||||||||
INS20 | |||||||||
719X | |||||||||
Sun et al. 2011[37] | ADC (39), SCC (31), ADSQ (6), LCC (4) | 80 | Ever (49) | Direct sequencing | all | Lymph nodes | |||
Never (31) | |||||||||
Global | 92,5% (74/80) | ||||||||
Wei et al. 2014[41] | ADC (49) | 50 | Ever (10) | 80% | qPCR (commercial kit) | 45 hotspots | Lymph nodes | ||
SCC (1) | |||||||||
Never (40) | 97,5% | ||||||||
Global | 93% (47/50) | ||||||||
Bai et al. 2013[36] | ADC (63) | 85 (45 EGFRmt 40 EGFRwt) | 1431 foci | 87,1% | ARMS | DXS EGFR mutation Kit | |||
SCC (10) | 1238 foci (foci : capture with laser microdissection 0,1cm2) | 4 cases with 5% - 8% of foci showing mutations | |||||||
ADSQ (5) | |||||||||
Other (7) | |||||||||
Chang et al. 2011[42] | ADC (34) | 56 (27 EGFRmt) | Ever (29) | 62% | Direct sequencing | all | Lymph nodes | ||
SCC (17) | |||||||||
ADSQ (1) | Never (23) | 70% | |||||||
Other (1) | Unknown (4) | ||||||||
Global | 68% (38/56) | ||||||||
Schmid et al. 2009[33] | ADC (96) | 96 (7 EGFRmt) | Ever (74) | Direct sequencing | L858R (3) | Lymph nodes | |||
DEL19 (3) | |||||||||
Never (22) | INS20 (1) | ||||||||
Global | 14% (1/7) | ||||||||
Gow et al 2009[34] | ADC (42) | 67 (35 EGFRmt) | Ever (26) | Direct sequencing and ARMS for discordant results | all | Brain (25) | |||
SCC (21) | Bone (20) | ||||||||
ADSQ (0) | (19 with adjuvant treatment before molecular analysis on metastatic site) | Never (41) | Other (22) | ||||||
Other (4) | Global | 26% (9/35) seq and 57 %(20/35) ARMS | |||||||
Mattsson et al. 2012[18] | ADC (6) | 6 | 3 foci per tumor (distinct morphologies) | 100% | Direct sequencing | L858R and DEL19 | |||
Kalikaki et al. 2008[35] | ADC (20) | 25 (7 EGFRmt) | Ever (22) | Direct sequencing | all | Brain (3) | |||
SCC (2) | Pleura (5) | ||||||||
ADSQ (0) | (17 with adjuvant treatment before molecular analysis on metastatic site) | Never (3) | Lung (9) | ||||||
Other (3) | Global | 14% (1/7) 5 mutations are rare alterations (codons 692-847-746-857) | Adrenal gland (3) | ||||||
Bone (2) | |||||||||
Skin (1) | |||||||||
Liver (1) | |||||||||
Matsumoto et al. 2006[43] | ADC (19) | 19 (12 EGFRmut) | 100% | Direct sequencing | L858R, DEL19 | Brain (19) | |||
Yatabe et al. 2011[17] | ADC (50) | 50 EGFRmt | 3 foci per tumor (50) | 100% | qPCR | L858R | |||
Fragment analysis | DEL19 | ||||||||
100 foci per tumor (5) | 100% |